Schedule 13G ownership disclosure

Aclaris Therapeutics Inc

Common Stock, $0.00001 par value · CUSIP: 00461U105

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Rock Springs Capital Management LP

    Shares: 5,046,309.00 · Class: 4.7%

  • Rock Springs Capital LLC

    Shares: 5,046,309.00 · Class: 4.7%

  • Rock Springs Capital Master Fund LP

    Shares: 0.00 · Class: 0%

  • Mark Bussard

    Shares: 5,046,309.00 · Class: 4.7%

  • Kris Jenner

    Shares: 5,046,309.00 · Class: 4.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001172661-25-002072
Form type
SCHEDULE 13G/A
Filer
Aclaris Therapeutics, Inc.
CIK
CIK 1557746
Filed
May 15, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub